Research programme: amyotrophic lateral sclerosis therapeutics - Eli Lilly/Project ALS
Latest Information Update: 21 Nov 2013
At a glance
- Originator Eli Lilly; Project A.L.S.
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 19 Nov 2013 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)